Swiss National Bank Has $1.18 Million Stock Position in Orthofix Medical Inc. (NASDAQ:OFIX)

Swiss National Bank grew its holdings in Orthofix Medical Inc. (NASDAQ:OFIX) by 2.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 67,600 shares of the medical device company’s stock after purchasing an additional 1,700 shares during the period. Swiss National Bank owned about 0.18% of Orthofix Medical worth $1,180,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. R Squared Ltd acquired a new stake in Orthofix Medical in the 4th quarter valued at $50,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Orthofix Medical by 5.9% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,994 shares of the medical device company’s stock valued at $156,000 after acquiring an additional 559 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in Orthofix Medical during the third quarter worth about $270,000. Inceptionr LLC acquired a new position in Orthofix Medical during the fourth quarter valued at approximately $279,000. Finally, Franklin Resources Inc. grew its stake in Orthofix Medical by 37.4% in the third quarter. Franklin Resources Inc. now owns 20,960 shares of the medical device company’s stock valued at $337,000 after purchasing an additional 5,702 shares in the last quarter. Institutional investors own 89.76% of the company’s stock.

Orthofix Medical Trading Down 0.6 %

OFIX stock opened at $16.06 on Friday. The stock has a market cap of $626.69 million, a price-to-earnings ratio of -5.13 and a beta of 1.06. The company has a fifty day moving average price of $17.63 and a two-hundred day moving average price of $17.37. Orthofix Medical Inc. has a one year low of $12.08 and a one year high of $20.73. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.39 and a quick ratio of 1.11.

Insider Buying and Selling

In related news, CFO Julie Andrews sold 4,655 shares of Orthofix Medical stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $17.89, for a total transaction of $83,277.95. Following the completion of the sale, the chief financial officer now directly owns 28,312 shares of the company’s stock, valued at approximately $506,501.68. This trade represents a 14.12 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Massimo Calafiore sold 10,078 shares of the company’s stock in a transaction on Friday, January 10th. The shares were sold at an average price of $16.83, for a total value of $169,612.74. Following the completion of the transaction, the chief executive officer now directly owns 133,354 shares in the company, valued at approximately $2,244,347.82. This represents a 7.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 29,999 shares of company stock valued at $512,497. Company insiders own 2.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on OFIX. Canaccord Genuity Group reiterated a “buy” rating and set a $24.00 price objective on shares of Orthofix Medical in a research note on Wednesday, February 26th. StockNews.com upgraded shares of Orthofix Medical from a “hold” rating to a “buy” rating in a research note on Tuesday, February 25th. Finally, Roth Mkm reiterated a “buy” rating and issued a $22.00 target price on shares of Orthofix Medical in a research note on Wednesday, February 26th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $23.33.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.